Active, not recruitingPhase 1NCT03598244
Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors
Studying Diffuse intrinsic pontine glioma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Ralph Salloum, M.DPediatric Brain Tumor Consortium
- Intervention
- Biospecimen Collection(procedure)
- Enrollment
- 41 enrolled
- Eligibility
- 6-21 years · All sexes
- Timeline
- 2018 – 2026
Study locations (12)
- Children's Hospital Los Angeles, Los Angeles, California, United States
- Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States
- Children's Hospital Colorado, Aurora, Colorado, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- Lurie Children's Hospital-Chicago, Chicago, Illinois, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
- Nationwide Children's Hospital, Columbus, Ohio, United States
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
- Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
- Texas Children's Hospital, Houston, Texas, United States
- Hospital for Sick Children, Toronto, Ontario, Canada
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03598244 on ClinicalTrials.govOther trials for Diffuse intrinsic pontine glioma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07076498Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standard of Care RadiationM.D. Anderson Cancer Center
- RECRUITINGPHASE1, PHASE2NCT07501156H3K27M-specific Immune Effector Cells Targeting DMG/DIPGShenzhen Geno-Immune Medical Institute
- RECRUITINGPHASE2NCT06838676ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade GliomasNationwide Children's Hospital
- RECRUITINGPHASE1NCT06305910CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young AdultsOX2 Therapeutics
- RECRUITINGPHASE1NCT06221553Safety and Efficacy of Loco-regional B7H3 IL-7Ra CAR T Cell in DIPGChulalongkorn University
- RECRUITINGPHASE1NCT05544526CAR T Cells to Target GD2 for DMGUniversity College, London
- RECRUITINGPHASE1NCT05762419FUS Etoposide for DMGColumbia University
- ACTIVE NOT RECRUITINGPHASE1NCT05768880Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System TumorsSeattle Children's Hospital